Magnolia Bark

Metadata

Approved Indications

European Regulatory Bodies

Magnolia bark has not been assessed by any of the three major European phytotherapy regulatory bodies:

• Commission E (Germany): No monograph exists. Magnolia bark was never part of the European herbal tradition evaluated by Commission E.
• ESCOP: No monograph. Not within the scope of European scientific cooperative assessment.
• EMA/HMPC: No assessment report or monograph. The herb is not listed in the EU herbal substances inventory.

This is not a negative assessment — these bodies simply never evaluated it, as it originates from the Chinese (TCM) and Japanese (Kampo) medical traditions rather than the European phytotherapy tradition.

Chinese Pharmacopoeia

• Listed: Yes. Houpo (Magnoliae Officinalis Cortex) is an official drug in the Chinese Pharmacopoeia.
• Traditional indications: Abdominal distension, fullness, constipation, phlegm-dampness obstruction of the lung, cough with dyspnea.

Japanese Pharmacopoeia

• Listed: Yes. Magnolia bark (Koboku) is an official Kampo crude drug.
• Used in formulas: Hange-koboku-to (Banxia Houpo Tang), Saiboku-to (Chai Pu Tang), and others.

United States

• FDA GRAS status: Magnolia bark extract has Generally Recognized as Safe (GRAS) status for use in food and beverages (GRN No. 549).
• Dietary supplement: Widely available as a dietary supplement under DSHEA.

Conditions Treated

Primary (Moderate Evidence)

• Anxiety and stress — Honokiol and magnolol demonstrate anxiolytic effects in animal models comparable to diazepam; Relora clinical trials show cortisol reduction and stress symptom improvement.
• Sleep disturbances — GABA-A modulation provides mild sedative effects; Relora studies show improved sleep quality in stressed individuals.

Secondary (Preliminary Evidence)

• Digestive complaints — Traditional TCM indication supported by preclinical evidence of GI antispasmodic and prokinetic effects.
• Stress-related overeating and weight management — Relora studies show reduced cortisol and stress-related eating behavior.

Emerging/Preclinical

• Neuroprotection — Honokiol demonstrates neuroprotective effects in multiple in vitro and animal models (anti-inflammatory, antioxidant, anti-amyloid aggregation).
• Oral health — Magnolol and honokiol show potent antibacterial activity against oral pathogens; used commercially in mouthwash and chewing gum products.
• Anti-cancer — Honokiol has been widely studied as an anti-cancer agent in preclinical models (NF-kB inhibition, apoptosis induction); no clinical trials.

Mechanism of Action

Primary Mechanisms

1. GABA-A receptor positive allosteric modulation: Honokiol is a positive allosteric modulator of GABA-A receptors, binding at a site distinct from the benzodiazepine binding site. It enhances GABAergic neurotransmission with subunit selectivity (preferring alpha-2/3 containing receptors), which may account for its anxiolytic effects with relatively less sedation and motor impairment compared to classical benzodiazepines. Magnolol also modulates GABA-A receptors but with a different subunit selectivity profile.

2. HPA axis modulation and cortisol reduction: Both honokiol and magnolol reduce cortisol output in stressed animal models. The Relora combination product demonstrated significant salivary cortisol reduction in human trials, suggesting downregulation of HPA axis hyperactivity.

3. NF-kB pathway inhibition: Honokiol is a potent inhibitor of the NF-kB signaling pathway, which mediates its anti-inflammatory, neuroprotective, and potential anti-cancer effects.

Secondary Mechanisms

4. GI antispasmodic and prokinetic effects: Magnolol relaxes smooth muscle in the GI tract and promotes gastric motility, consistent with traditional TCM indications for abdominal fullness and distension.

5. Cannabinoid receptor interaction: Honokiol has partial agonist activity at CB1 receptors, which may contribute to anxiolytic and analgesic effects.

6. Antioxidant activity: Both honokiol and magnolol are potent lipid peroxidation inhibitors, approximately 1000x more potent than alpha-tocopherol in some in vitro assays.

Key Pharmacological Note

Honokiol’s GABA-A modulation is mechanistically similar to kava’s kavalactones and distinct from benzodiazepines. Both honokiol and kavalactones modulate GABA-A receptors through interaction with the lipid membrane environment rather than direct binding at the benzodiazepine site. This shared mechanism suggests a potentially similar clinical profile: anxiolysis with less sedation and cognitive impairment.

Clinical Evidence Summary

Clinical evidence for magnolia bark is limited and is primarily derived from studies using the combination product Relora (Magnolia officinalis + Phellodendron amurense), making it difficult to isolate the effects of magnolia bark alone.

Relora Combination Product Trials

Japanese Kampo Formula Studies

• Hange-koboku-to (Banxia Houpo Tang): Several small Japanese studies demonstrate anxiolytic and antidepressant effects of this magnolia bark-containing Kampo formula. However, the formula contains five herbs, making it impossible to attribute effects to magnolia bark alone.
• Saiboku-to (Chai Pu Tang): Studied for asthma and anxiety; contains magnolia bark among multiple herbs.

Standalone Magnolia Bark Studies

• No published placebo-controlled RCTs of standalone magnolia bark extract for anxiety or sleep in Western populations.
• Several preclinical studies provide strong mechanistic rationale, but the gap between preclinical and clinical evidence remains significant.

Evidence Limitations

• Most human data comes from Relora, a combination product — effects cannot be attributed to magnolia bark alone.
• Sample sizes are small (n=26-56).
• The Kalman (2008) and Garrison (2006) studies lacked placebo control.
• Japanese Kampo studies use multi-herb formulas.
• No long-term safety or efficacy data beyond 6 weeks.

Safety Profile

General Assessment

Magnolia bark extract appears to be generally well-tolerated in published clinical trials and has a long history of use in TCM (>2000 years). However, systematic safety data from large controlled trials is lacking.

Contraindications

• Pregnancy: Contraindicated. Honokiol has demonstrated uterotonic activity in animal studies. No human safety data in pregnancy.
• Lactation: Insufficient data. Avoid until safety is established.
• Pre-surgical: Discontinue at least 2 weeks before surgery due to potential additive effects with anesthetic agents.

Drug Interactions

• CNS depressants (benzodiazepines, barbiturates, alcohol, opioids): Theoretical additive sedation due to GABA-A modulation. No clinical case reports, but mechanistic concern is warranted.
• CYP450 substrates: In vitro studies suggest honokiol and magnolol inhibit CYP1A2, CYP2C8, CYP2C9, and CYP3A4. Clinical significance is uncertain but caution is advised with narrow therapeutic index drugs metabolized by these enzymes.
• Anticoagulants/antiplatelets: Magnolol has demonstrated antiplatelet activity in vitro. Theoretical increased bleeding risk.

Side Effects (at recommended doses)

• Common: Generally well-tolerated; mild GI discomfort reported occasionally.
• Uncommon: Drowsiness, headache, dizziness (consistent with GABA-A modulation).
• Reported in Relora trials: Mild heartburn, shaking hands, thyroid dysfunction, sexual dysfunction, and headache were reported but not statistically different from placebo.

Toxicology

• Acute oral LD50 of honokiol in mice: >5 g/kg (very low acute toxicity).
• No evidence of genotoxicity or mutagenicity in standard assays.
• No hepatotoxicity signal in clinical trials (in contrast to kava), though systematic monitoring has not been performed.

Clinical Dosage

Relora (Combination Product)

• Standard dose: 250 mg three times daily (750 mg/day total)
• Standardization: Proprietary blend of Magnolia officinalis and Phellodendron amurense bark extracts
• This is the most clinically studied dose form

Standalone Magnolia Bark Extract

• Typical dose: 200-400 mg/day of bark extract standardized to 2% honokiol + magnolol
• Higher-potency extracts: Some products are standardized to 90%+ honokiol; doses of 50-200 mg/day for these concentrated forms
• Note: Standalone extract dosing is largely empirical, not derived from controlled clinical trials

Traditional Chinese Medicine (Decoction)

• Houpo (bark): 3-10 g daily in decoction
• Typically combined with other herbs in formula (not used as single-herb therapy in TCM)

Sources

• Talbott SM, Talbott JA, Pugh M. Effect of Magnolia officinalis and Phellodendron amurense (Relora) on cortisol and psychological mood state in moderately stressed subjects. J Int Soc Sports Nutr. 2013;10(1):37
• Kalman DS, Feldman S, Feldman R, et al. Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial. Nutr J. 2008;7:11
• Garrison R, Chambliss WG. Effect of a proprietary Magnolia and Phellodendron extract on weight management. Altern Ther Health Med. 2006;12(1):50-54
• Kuribara H, Stavinoha WB, Maruyama Y. Honokiol, a putative anxiolytic agent extracted from magnolia bark, has no diazepam-like side effects in mice. J Pharm Pharmacol. 1999;51(1):97-103
• Alexeev M, et al. A specific subtype of GABAA receptor modulation by a naturally occurring neolignan honokiol. Neuroscience. 2012;213:93-104
• Woodbury A, Yu SP, Wei L, Garcia P. Neuro-modulating effects of honokiol: a review. Front Neurol. 2013;4:130
• Poivre M, Duez P. Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents. J Integr Med. 2017;15(5):334-351
• Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Vol 1. 2020 Edition
• FDA GRAS Notice GRN No. 549. Magnolia bark extract. 2015

Connections

• Compare with other GABA-modulating anxiolytics: kava (kavalactones — similar lipid membrane GABA-A mechanism), valerian, passionflower
• The GABA-A positive allosteric modulation mechanism is shared with kava but distinct from benzodiazepines
• Contrast with European-tradition nervines: lemon balm, lavender (Silexan), hops
• Magnolia bark represents the growing integration of TCM-origin herbs into Western evidence-based phytotherapy